NEONC TECHNOLOGIES HOLDINGS, INC. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 78/100
What the filing says
NeOnc (market cap ~$67.9M) reported Q2 2026 results: net loss $14.2M ($0.58/share) vs. $5.7M ($0.30/share) YoY; R&D expenses increased to $2.6M from $0.7M reflecting expanded clinical trial sites, manufacturing, and NEO100 Phase 2a data analysis completion. The company secured UAE IND approvals for both NEO100 and NEO212 programs in June 2026. Cash position stood at $2.0M with $10M undrawn credit facility and $44.5M available under Mast Hill equity facility. Critical milestone: topline Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma to be presented August 12, 2026—company calls this "one of the most important clinical milestones in NeOnc's history."
Why this rating
Phase 2a data readout is pivotal catalyst for clinical-stage biotech; loss worsening but R&D-driven; cash burn accelerating vs. $67.9M market cap—high execution risk, outcome-dependent.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.